Home › Companies › IONIS PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and IONIS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 6, 2024: 5 items on IONIS PHARMACEUTICALS INC.’s Form 8-K, filed June 10, 2024: 2 elected · 3 approved.
Notable dissent: 1 director (11.5% against); 1 other board item (21.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore IONIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are IONIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Brett P. Monia | 120,462,201 | 2,850,850 | 157,065 | -- | 10,132,983 | 98% | Elected | — |
| Elect Director: Michael Yang | 109,136,314 | 14,191,316 | 142,486 | -- | 10,132,983 | 88% | Elected | — |
| 2. Advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed | 118,899,475 | 4,228,901 | 341,740 | -- | 10,132,983 | 97% | Approved | — |
| 3. Approval of an amendment of the Ionis Pharmaceuticals, Inc | 96,453,407 | 26,912,642 | 104,067 | -- | 10,132,983 | 78% | Approved | — |
| 4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year | 129,900,428 | 3,455,435 | 247,236 | -- | 0 | 97% | Approved | — |
This meeting is also recorded here as June 7, 2024; both records come from the same filing, so the date should be checked against it.
Source: IONIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
409 asset managers disclosed a vote on at least one IONIS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Brett P. Monia
IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Brett P. Monia”): 120,462,201 for, 2,850,850 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2027 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 101 asset managers below reported 61,455,312 for, 161,530 against, 635 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,601,975 | 0 | 0 | 0 | For |
| Fidelity | 13,218,521 | 0 | 0 | 0 | For |
| T. Rowe Price | 10,283,039 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 2,954,743 | 0 | 0 | 0 | For |
| Waddell & Reed | 2,335,501 | 0 | 0 | 0 | For |
| BlackRock | 2,153,397 | 0 | 0 | 0 | For |
| Legg Mason | 1,726,610 | 0 | 0 | 0 | For |
| State Street | 1,477,809 | 6,071 | 0 | 0 | For |
| ARK ETF Trust | 1,385,268 | 0 | 0 | 0 | For |
| Charles Schwab | 1,295,535 | 0 | 0 | 0 | For |
| Jackson National | 849,000 | 116,716 | 0 | 0 | Mixed |
| Capital Group | 839,463 | 0 | 0 | 0 | For |
| Invesco | 648,901 | 0 | 0 | 0 | For |
| MassMutual | 630,000 | 0 | 0 | 0 | For |
| TIAA | 387,417 | 0 | 0 | 0 | For |
| John Hancock | 293,466 | 0 | 0 | 0 | For |
| Empower | 285,377 | 0 | 0 | 0 | For |
| Artisan | 243,854 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 231,201 | 0 | 0 | 0 | For |
| Aberdeen | 219,421 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 215,677 | 0 | 0 | 0 | For |
| Pacific Life | 184,654 | 0 | 0 | 0 | For |
| Northwestern Mutual | 130,027 | 0 | 0 | 0 | For |
| PIONEER SERIES TRUST XII | 123,156 | 0 | 0 | 0 | For |
| Hartford | 123,041 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. All 101 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Michael Yang
IONIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael Yang”): 109,136,314 for, 14,191,316 against, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of directors to hold office until the 2027 Annual Meeting: The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 101 asset managers below reported 52,161,258 for, 9,455,585 against, 635 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,601,975 | 0 | 0 | 0 | For |
| Fidelity | 13,218,521 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,687,377 | 7,595,662 | 0 | 0 | Mixed |
| TWEEDY, BROWNE FUND INC. | 2,954,743 | 0 | 0 | 0 | For |
| Waddell & Reed | 2,335,501 | 0 | 0 | 0 | For |
| BlackRock | 2,153,397 | 0 | 0 | 0 | For |
| Legg Mason | 1,726,610 | 0 | 0 | 0 | For |
| State Street | 1,483,880 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,385,268 | 0 | 0 | 0 | For |
| Charles Schwab | 1,295,535 | 0 | 0 | 0 | For |
| Jackson National | 116,716 | 849,000 | 0 | 0 | Mixed |
| Capital Group | 839,463 | 0 | 0 | 0 | For |
| Invesco | 648,901 | 0 | 0 | 0 | For |
| MassMutual | 0 | 630,000 | 0 | 0 | Against |
| TIAA | 387,417 | 0 | 0 | 0 | For |
| John Hancock | 281,280 | 12,186 | 0 | 0 | For |
| Empower | 12,077 | 273,300 | 0 | 0 | Against |
| Artisan | 243,854 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 231,201 | 0 | 0 | 0 | For |
| Aberdeen | 219,421 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 215,677 | 0 | 0 | 0 | For |
| Pacific Life | 184,654 | 0 | 0 | 0 | For |
| Northwestern Mutual | 73,127 | 56,900 | 0 | 0 | Mixed |
| PIONEER SERIES TRUST XII | 123,156 | 0 | 0 | 0 | For |
| Hartford | 123,041 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. All 101 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
78% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT OF THE IONIS PHARMACEUTICALS, INC. 2011 EQUITY INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER SUCH PLAN BY 3,300,000 SHARES TO AN AGGREGATE OF 38,500,000 SHARES AND TO PROHIBIT CERTAIN SHARE RECYCLING ON FULL VALUE AWARDS.
IONIS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval of an amendment of the Ionis Pharmaceuticals, Inc”): 96,453,407 for, 26,912,642 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 101 asset managers below reported 47,546,009 for, 14,024,680 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,601,975 | 0 | 0 | 0 | For |
| Fidelity | 2,220,781 | 10,997,740 | 0 | 0 | Mixed |
| T. Rowe Price | 10,283,039 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 0 | 2,954,743 | 0 | 0 | Against |
| Waddell & Reed | 2,335,501 | 0 | 0 | 0 | For |
| BlackRock | 2,153,397 | 0 | 0 | 0 | For |
| Legg Mason | 1,726,610 | 0 | 0 | 0 | For |
| State Street | 1,483,221 | 659 | 0 | 0 | For |
| ARK ETF Trust | 1,385,268 | 0 | 0 | 0 | For |
| Charles Schwab | 1,295,535 | 0 | 0 | 0 | For |
| Jackson National | 965,716 | 0 | 0 | 0 | For |
| Capital Group | 839,463 | 0 | 0 | 0 | For |
| Invesco | 648,901 | 0 | 0 | 0 | For |
| MassMutual | 630,000 | 0 | 0 | 0 | For |
| TIAA | 387,417 | 0 | 0 | 0 | For |
| John Hancock | 293,466 | 0 | 0 | 0 | For |
| Empower | 285,377 | 0 | 0 | 0 | For |
| Artisan | 243,854 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 231,201 | 0 | 0 | 0 | For |
| Aberdeen | 219,421 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 215,677 | 0 | 0 | 0 | For |
| Pacific Life | 184,654 | 0 | 0 | 0 | For |
| Northwestern Mutual | 130,027 | 0 | 0 | 0 | For |
| PIONEER SERIES TRUST XII | 123,156 | 0 | 0 | 0 | For |
| Hartford | 123,041 | 0 | 0 | 0 | For |
Showing the 25 largest of 101 asset managers. All 101 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 97.7% for (June 1, 2023 meeting) ▼ 1.1 pts
Description as filed by funds: To make an advisory vote on executive compensation.
IONIS PHARMACEUTICALS INC.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 118,899,475 for, 4,228,901 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,601,975 | 0 | 0 | 0 | For |
| Fidelity | 13,218,521 | 0 | 0 | 0 | For |
| T. Rowe Price | 10,283,039 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 2,954,743 | 0 | 0 | 0 | For |
| Waddell & Reed | 2,335,501 | 0 | 0 | 0 | For |
| BlackRock | 2,153,397 | 0 | 0 | 0 | For |
| Legg Mason | 1,726,610 | 0 | 0 | 0 | For |
| State Street | 1,480,344 | 3,536 | 0 | 0 | For |
| ARK ETF Trust | 1,385,268 | 0 | 0 | 0 | For |
| Charles Schwab | 1,295,535 | 0 | 0 | 0 | For |
| Jackson National | 965,716 | 0 | 0 | 0 | For |
| Capital Group | 839,463 | 0 | 0 | 0 | For |
| Invesco | 648,901 | 0 | 0 | 0 | For |
| MassMutual | 630,000 | 0 | 0 | 0 | For |
| Artisan | 563,948 | 0 | 0 | 0 | For |
| TIAA | 387,417 | 0 | 0 | 0 | For |
| John Hancock | 293,466 | 0 | 0 | 0 | For |
| Empower | 285,377 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 231,201 | 0 | 0 | 0 | For |
| Aberdeen | 219,421 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 215,677 | 0 | 0 | 0 | For |
| Pacific Life | 184,654 | 0 | 0 | 0 | For |
| Northwestern Mutual | 130,027 | 0 | 0 | 0 | For |
| PIONEER SERIES TRUST XII | 123,156 | 0 | 0 | 0 | For |
| Hartford | 123,041 | 0 | 0 | 0 | For |
Fund voting reports, all 98 managers: 61,796,268 for, 78,046 against, 1 withheld, 11,636 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 20,487,244 | 0 | 0 | 0 | For |
| T. Rowe Price | 16,392,356 | 0 | 0 | 0 | For |
| Wellington | 5,419,781 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 4,353,081 | 0 | 0 | 0 | For |
| BlackRock | 3,526,251 | 14,620 | 0 | 0 | For |
| Tweedy, Browne Co LLC | 3,454,676 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 3,092,500 | 0 | 0 | 0 | For |
| State Street | 3,044,723 | 3,931 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 2,647,321 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,428,613 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,308,078 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 2,013,033 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,492,451 | 0 | 0 | 0 | For |
| Charles Schwab | 1,301,673 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 908,486 | 0 | 0 | Against |
| Capital Group | 839,484 | 125 | 0 | 0 | For |
| Man Group plc | 824,080 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 733,334 | 0 | 0 | Against |
| Invesco | 718,852 | 0 | 0 | 0 | For |
| Two Sigma | 639,391 | 0 | 0 | 0 | For |
| Point72 | 566,735 | 0 | 0 | 0 | For |
| JPMorgan | 552,748 | 0 | 0 | 0 | For |
| Northern Trust | 448,560 | 100 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 446,603 | 0 | 0 | 0 | For |
| Nuveen | 398,585 | 0 | 0 | 0 | For |
Institutional-manager reports, all 336 managers: 85,703,246 for, 3,087,928 against, 247 withheld, 78,404 abstained, 519 not voted, 4 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 98.2% for (June 1, 2023 meeting) ▼ 0.8 pts
Description as filed by funds: TO RATIFY THE AUDIT COMMITTEE'S SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT AUDITORS FOR THE 2024 FISCAL YEAR.
IONIS PHARMACEUTICALS INC.’s own tally for this item (“4. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2024 fiscal year”): 129,900,428 for, 3,455,435 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 102 asset managers below reported 61,365,161 for, 240,780 against, 1 withheld, 11,636 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 17,601,975 | 0 | 0 | 0 | For |
| Fidelity | 13,218,521 | 0 | 0 | 0 | For |
| T. Rowe Price | 10,283,039 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 2,954,743 | 0 | 0 | 0 | For |
| Waddell & Reed | 2,335,501 | 0 | 0 | 0 | For |
| BlackRock | 2,153,397 | 0 | 0 | 0 | For |
| Legg Mason | 1,726,610 | 0 | 0 | 0 | For |
| State Street | 1,481,345 | 2,535 | 0 | 0 | For |
| ARK ETF Trust | 1,385,268 | 0 | 0 | 0 | For |
| Charles Schwab | 1,295,535 | 0 | 0 | 0 | For |
| Jackson National | 965,716 | 0 | 0 | 0 | For |
| Capital Group | 839,463 | 0 | 0 | 0 | For |
| Invesco | 648,901 | 0 | 0 | 0 | For |
| MassMutual | 630,000 | 0 | 0 | 0 | For |
| TIAA | 387,417 | 0 | 0 | 0 | For |
| John Hancock | 293,466 | 0 | 0 | 0 | For |
| Empower | 285,377 | 0 | 0 | 0 | For |
| Artisan | 243,854 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 231,201 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 219,421 | 0 | 0 | Against |
| Delaware/Macquarie | 215,677 | 0 | 0 | 0 | For |
| Pacific Life | 184,654 | 0 | 0 | 0 | For |
| Northwestern Mutual | 130,027 | 0 | 0 | 0 | For |
| PIONEER SERIES TRUST XII | 123,156 | 0 | 0 | 0 | For |
| Hartford | 123,041 | 0 | 0 | 0 | For |
Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 145,844,719 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.07% |
| 2 | Fidelity | 9.06% |
| 3 | T. Rowe Price | 7.05% |
| 4 | TWEEDY, BROWNE FUND INC. | 2.03% |
| 5 | Waddell & Reed | 1.60% |
| 6 | BlackRock | 1.48% |
| 7 | Legg Mason | 1.18% |
| 8 | State Street | 1.02% |
| 9 | ARK ETF Trust | 0.95% |
| 10 | Charles Schwab | 0.89% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.05% |
| 2 | T. Rowe Price | 11.24% |
| 3 | Wellington | 3.72% |
| 4 | Clearbridge Investments, LLC | 2.98% |
| 5 | BlackRock | 2.43% |
| 6 | Tweedy, Browne Co LLC | 2.37% |
| 7 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2.12% |
| 8 | State Street | 2.09% |
| 9 | PICTET ASSET MANAGEMENT SA | 1.82% |
| 10 | BVF INC/IL | 1.67% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 23,689,038 | 16.24% | Form 13F, quarter ended March 31, 2024 |
| FMR LLC | 21,520,872 | 14.76% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| Vanguard Group | 16,481,730 | 11.30% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 10,447,940 | 7.16% | Form 13F, quarter ended March 31, 2024 |
| Black Rock, Inc. | 9,057,282 | 6.21% | Proxy statement (DEF 14A), proxy filed April 25, 2024 |
| State Street | 4,155,664 | 2.85% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 3,522,203 | 2.42% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 2,364,256 | 1.62% | Form 13F, quarter ended March 31, 2024 |
| Charles Schwab | 1,301,368 | 0.89% | Form 13F, quarter ended March 31, 2024 |
| Morgan Stanley | 1,180,316 | 0.81% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 145,844,719 shares outstanding, as reported by IONIS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At IONIS PHARMACEUTICALS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 409 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,097 separate fund positions. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — IONIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: IONIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IONIS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
IONIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “IONIS PHARMACEUTICALS (IONS) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ionis-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.